Endocrine Abstracts

Objectives: To assess baseline differences on lipid profile in individuals with gender identity disorder (male to female, M2F and female to male, F2M) in relation to prior cross-sex hormone treatment (CHT) or not, and changes in the lipid profile after 24 months of treatment and follow-up in our unit.Methods: Transversal study by revision of medical records of 235 patients visited for first time in our service from 2006 to 2010. Clinical and analytical r...

Objectives: Most transgender persons (0.3-0.5% of total population) are under gender-affirming hormone therapy (GAHT). Several studies have reported an increased morbimortality due to cardiovascular events (CVE), infectious disease and suicide. However, these studies were made on small populations and short follow up. We evaluated the changes on anthropometric variables, risk factors for cardiovascular diseases (CVD) and CVE at 5 and 10 years of follow up in a transgender popu...

Ntroduction and Aim: The use of sodium-glucose cotransporter type 2 (SGLT-2) inhibitors has importantly improved the management of patients with type 2 diabetes mellitus. The aim of the present study was to evaluate the renal and metabolic effects after one year of SGLT-2 use in a cohort of patients with type 1 diabetes mellitus (T1D) treated with continuous subcutaneous insulin infusion (CSII).Methods: Retrospective observational study in adult patients...

Background and Aim: Data support the use of hybrid closed-loop systems, because of it positive impact in the management of patients with type 1 diabetes (T1D). The aim was to evaluate the impact of an hybrid closed-loop system in patients with T1D at high risk of hypoglycemia.Methods: Retrospective study of patients with T1D controlled in a Endocrinology department older than 17 years old, who were carriers of an Insulin Pump (MiniMed™640G) and Flas...